510(k) Report

PMA · Approved

Approved

Progensa PCA3 Assay

P100033PMAApproved Feb 13, 2012552-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Gen-Probe Incorporated · OYM Prostrate Cancer Genes Nucleic Acid Amplification Test System

Approved on Feb 13, 2012 through premarket approval, which rests on the device’s own clinical evidence after a 552-day review.

Decided
Feb 13, 2012
Review
552 days
Class
Class III
Product code
OYM
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

P100033 has 12 supplements since 2013: changes to the approved device, its labelling or its manufacturing, each approved separately.

PMA supplements approved per year

2013: 12015: 52017: 12018: 22019: 12020: 2
2013high 5 (2015) · low 0 (2014)2020
View FIG. 1 as a table
YearSupplements approved
20131
20155
20171
20182
20191
20202
FIG. 1 — Supplements to P100033, 2013–2020Source: FDA PMA database

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in OYM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All OYM devices

OYM Prostrate Cancer Genes Nucleic Acid Amplification Test System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2012, this device’s year, is highlighted.

FDA decisions per year · OYM

2in 2020

2012: 12013: 12015: 52017: 12018: 22019: 12020: 2
2007high 5 (2015) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · OYM

Too few OYM 510(k)s in any year since 2007 to give a median.

Recalls per year · OYM

No recall names OYM since 2007.

Adverse event reports per year · OYM

No MAUDE report names OYM since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20121—00
20131—00
20140—00
20155—00
20160—00
20171—00
20182—00
20191—00
20202—00
20210—00
20220—00
20230—00
20240—00
20250—00
20260—0—
Cite this page

510(k) Report. “P100033: Progensa PCA3 Assay.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/P100033

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026